Arena Pharmaceuticals, Inc, a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include ralinepag (APD811), which is in Phase III trial to treat pulmonary arterial hypertension; etrasimod (APD334) for ulcerative colitis, and Crohn's disease, as well as for atopic dermatitis and other indications; and Olorinab (APD371), which is in Phase II trial for the treatment of gastrointestinal pain.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone858-453-7200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$17.97 million
Profitability
Miscellaneous
Employees194
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Arena Pharmaceuticals (NASDAQ:ARNA) Frequently Asked Questions
What is Arena Pharmaceuticals' stock symbol?
Arena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ARNA."
When did Arena Pharmaceuticals' stock split? How did Arena Pharmaceuticals' stock split work?
Arena Pharmaceuticals's stock reverse split on Monday, June 19th 2017. The 1-10 reverse split was announced on Wednesday, June 14th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 16th 2017. An investor that had 100 shares of Arena Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.
How were Arena Pharmaceuticals' earnings last quarter?
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) issued its earnings results on Wednesday, August, 7th. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing analysts' consensus estimates of ($1.02) by $0.22. The biopharmaceutical company earned $1.02 million during the quarter, compared to analysts' expectations of $2.91 million. Arena Pharmaceuticals had a return on equity of 53.92% and a net margin of 72.84%. The company's revenue for the quarter was down 74.4% compared to the same quarter last year. During the same quarter last year, the company earned ($0.65) earnings per share. View Arena Pharmaceuticals' Earnings History.
When is Arena Pharmaceuticals' next earnings date?
What price target have analysts set for ARNA?
5 brokers have issued 12-month price objectives for Arena Pharmaceuticals' shares. Their forecasts range from $55.00 to $79.00. On average, they expect Arena Pharmaceuticals' stock price to reach $66.60 in the next year. This suggests a possible upside of 38.2% from the stock's current price. View Analyst Price Targets for Arena Pharmaceuticals.
What is the consensus analysts' recommendation for Arena Pharmaceuticals?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arena Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arena Pharmaceuticals.
What are Wall Street analysts saying about Arena Pharmaceuticals stock?
Here are some recent quotes from research analysts about Arena Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Arena Pharmaceuticals reported impressive first-quarter results wherein earnings and sales surpassed the respective estimates. The company is focused on developing its two pipeline candidates – etrasimod and olorinab. The company out-licensed ralinepag to United Therapeutics and the fund is being used to support continuation of clinical development of other candidates. Meanwhile, the company’s decision to sell its manufacturing operations to focus on the pipeline is prudent, in our view. However, Arena’s pipeline candidates are in mid-stage development, which is a concern as any setback will have a negative impact on Arena’s prospects. Dependence on Belviq royalties is also concerning as the drug’s performance has been lackluster lately in a competitive market. Shares of the company have outperformed the industry so far this year." (5/15/2019)
- 2. Cantor Fitzgerald analysts commented, ": We reiterate our Overweight and $62 PT. Arena today reported 1Q financials and provided an update on its clinical programs, including details on the etrasimod Ph3 trial design in ulcerative colitis (UC) that is still expected to initiate mid-year. We think the planned Ph3 UC program is strategically designed to expedite enrollment and support a differentiated commercial profile for etrasimod. We continue to believe IBD represents a large and growing market, and etrasimod is well-positioned in UC with potential to expand into other I&I indications due to its safety profile." (5/8/2019)
Has Arena Pharmaceuticals been receiving favorable news coverage?
Media headlines about ARNA stock have been trending somewhat positive on Wednesday, according to InfoTrie Sentiment Analysis. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Arena Pharmaceuticals earned a news sentiment score of 2.0 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Arena Pharmaceuticals.
Are investors shorting Arena Pharmaceuticals?
Arena Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,210,000 shares, an increase of 5.2% from the August 30th total of 3,050,000 shares. Based on an average daily trading volume, of 452,100 shares, the short-interest ratio is presently 7.1 days. Currently, 6.5% of the shares of the stock are short sold. View Arena Pharmaceuticals' Current Options Chain.
Who are some of Arena Pharmaceuticals' key competitors?
Some companies that are related to Arena Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Array Biopharma (ARRY), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS).
What other stocks do shareholders of Arena Pharmaceuticals own?
Who are Arena Pharmaceuticals' key executives?
Arena Pharmaceuticals' management team includes the folowing people:
- Mr. Amit D. Munshi, Pres, CEO & Director (Age 51)
- Mr. Kevin R. Lind, Exec. VP & CFO (Age 43)
- Mr. Steven W. Spector, Exec. VP, Gen. Counsel & Sec. (Age 54)
- Mr. Vincent E. Aurentz, Exec. VP & Chief Bus. Officer (Age 51)
- Dr. Preston S. Klassen, Exec. VP of R&D and Chief Medical Officer (Age 50)
Who are Arena Pharmaceuticals' major shareholders?
Arena Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.31%), Robeco Institutional Asset Management B.V. (0.16%), Bailard Inc. (0.14%), Virginia Retirement Systems ET AL (0.05%), Convergence Investment Partners LLC (0.05%) and Strs Ohio (0.05%). Company insiders that own Arena Pharmaceuticals stock include Jayson Donald Alexander Dallas, Preston Klassen, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Institutional Ownership Trends for Arena Pharmaceuticals.
Which institutional investors are selling Arena Pharmaceuticals stock?
ARNA stock was sold by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB and Exane Derivatives. Company insiders that have sold Arena Pharmaceuticals company stock in the last year include Jayson Donald Alexander Dallas, Preston Klassen, Steven W Spector, Tina Susan Nova and Vincent Aurentz. View Insider Buying and Selling for Arena Pharmaceuticals.
Which institutional investors are buying Arena Pharmaceuticals stock?
ARNA stock was purchased by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Bowling Portfolio Management LLC, Convergence Investment Partners LLC, Bailard Inc., Envestnet Asset Management Inc., Hexavest Inc., Nisa Investment Advisors LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Arena Pharmaceuticals.
How do I buy shares of Arena Pharmaceuticals?
Shares of ARNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arena Pharmaceuticals' stock price today?
One share of ARNA stock can currently be purchased for approximately $48.19.
How big of a company is Arena Pharmaceuticals?
Arena Pharmaceuticals has a market capitalization of $2.40 billion and generates $17.97 million in revenue each year. The biopharmaceutical company earns $-29,400,000.00 in net income (profit) each year or ($2.95) on an earnings per share basis. Arena Pharmaceuticals employs 194 workers across the globe.View Additional Information About Arena Pharmaceuticals.
What is Arena Pharmaceuticals' official website?
How can I contact Arena Pharmaceuticals?
Arena Pharmaceuticals' mailing address is 6154 Nancy Ridge Drive, San Diego CA, 92121. The biopharmaceutical company can be reached via phone at 858-453-7200 or via email at [email protected]
MarketBeat Community Rating for Arena Pharmaceuticals (NASDAQ ARNA)
MarketBeat's community ratings are surveys of what our community members think about Arena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ARNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
